NOT:ETR
Novartis AG
€133.36
arrow_downward
-0.91%(-1.22) 1D
Oct 19, 5:35:49 PM GMT+2 · EUR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOT...
Open
€134.88
High
€135.12
Low
€133.36
Mkt. cap
307.12B
Avg. vol.
7.39K
Volume
3.55K
52-wk high
€144.12
52-wk low
€104.52
No. of employees
75K
Open
€134.88
High
€135.12
Low
€133.36
Mkt. cap
307.12B
Avg. vol.
7.39K
Volume
3.55K
52-wk high
€144.12
52-wk low
€104.52
No. of employees
75K
News stories
From web sources and news partners
marketscreener.com
·
12 hours ago
Switzerland's Blue-chip Index Kicks Off Week Downbeat; Novartis Shares Decline
Yahoo Finance
·
15 hours ago
Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much?
ad-hoc-news.de
·
15 hours ago
Novartis stock: UBS keeps CHF 116.00 target for Novartis stock
ad-hoc-news.de
·
20 hours ago
Novartis ends Fabhalta trial while Novartis stock trades at EUR 134.82
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3K
FoundedMar 7, 1996
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websitenovartis.com
Next call in 7 days
Tue, Oct 27, 2:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.26
Revenue / Est. (USD)
- / 14.61B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 14.36B | 13.86B | 13.52B | 14.95B |
Cost of goods sold | 3.54B | 3.54B | 3.44B | 3.68B |
Cost of revenue | 3.54B | 3.54B | 3.44B | 3.68B |
Research and development expenses | 2.86B | 2.84B | 2.78B | 2.74B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.30B | 3.44B | 3.14B | 3.23B |
Operating expense | 6.24B | 6.46B | 5.96B | 6.10B |
Total operating expenses | 9.77B | 10.00B | 9.40B | 9.78B |
Operating income | 4.58B | 3.86B | 4.12B | 5.18B |
Other non operating income | -7.00M | -130.00M | 4.00M | 19.00M |
EBT including unusual items | 4.20B | 3.22B | 3.84B | 4.27B |
EBT excluding unusual items | 4.29B | 3.49B | 3.78B | 4.73B |
Income tax expense | 266.00M | 814.00M | 683.00M | 1.01B |
Effective tax rate | 6.34% | 25.30% | 17.79% | 23.71% |
Other operating expenses | 70.00M | 190.00M | 42.00M | 127.00M |
Net income | 3.93B | 2.41B | 3.16B | 3.26B |
Net profit margin | 27.36% | 17.38% | 23.34% | 21.83% |
Earnings per share | 2.25 | 2.03 | 1.99 | 2.41 |
Interest and investment income | - | 373.00M | - | - |
Interest expense | -281.00M | -304.00M | -343.00M | -462.00M |
Net interest expenses | -281.00M | 69.00M | -343.00M | -462.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 5.78B | 4.96B | 5.24B | 6.30B |
Gain or loss from assets sale | 81.00M | 80.00M | -159.00M | -247.00M |